The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).
Conditions
- Type 2 Diabetes Mellitus
Intervention
- Cagrilintide
- Semaglutide
- Placebo cagrilintide
- Placebo semaglutide
Principal Investigator
- Lee, Scott
Sponsor
- Novo Nordisk
*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 05/18/2024. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.
Request Information
Complete the form below to contact the study team and receive more information about this trial.